- Home
- TPST vs NRXP Comparison
TPST vs NRXP Comparison
Compare TPST & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- NRXP
- Stock Information
- Founded
- TPST 2011
- NRXP 2015
- Country
- TPST United States
- NRXP United States
- Employees
- TPST N/A
- NRXP N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- NRXP Health Care
- Exchange
- TPST Nasdaq
- NRXP Nasdaq
- Market Cap
- TPST 33.0M
- NRXP 32.6M
- IPO Year
- TPST N/A
- NRXP N/A
- Fundamental
- Price
- TPST $6.95
- NRXP $3.24
- Analyst Decision
- TPST Hold
- NRXP Strong Buy
- Analyst Count
- TPST 3
- NRXP 4
- Target Price
- TPST $30.00
- NRXP $28.50
- AVG Volume (30 Days)
- TPST 90.3K
- NRXP 204.8K
- Earning Date
- TPST 08-07-2025
- NRXP 08-13-2025
- Dividend Yield
- TPST N/A
- NRXP N/A
- EPS Growth
- TPST N/A
- NRXP N/A
- EPS
- TPST N/A
- NRXP N/A
- Revenue
- TPST N/A
- NRXP N/A
- Revenue This Year
- TPST N/A
- NRXP N/A
- Revenue Next Year
- TPST N/A
- NRXP N/A
- P/E Ratio
- TPST N/A
- NRXP N/A
- Revenue Growth
- TPST N/A
- NRXP N/A
- 52 Week Low
- TPST $5.35
- NRXP $1.10
- 52 Week High
- TPST $30.03
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- TPST 46.97
- NRXP 53.62
- Support Level
- TPST $7.06
- NRXP $2.90
- Resistance Level
- TPST $7.64
- NRXP $3.53
- Average True Range (ATR)
- TPST 0.27
- NRXP 0.20
- MACD
- TPST 0.02
- NRXP -0.04
- Stochastic Oscillator
- TPST 31.91
- NRXP 58.73
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.